ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

LY3873862

A development code.

Its studies are mostly in Amyotrophic Lateral Sclerosis, led by Eli Lilly.

Furthest: phase 1, since Aug 5, 20222 company-led studies, 1 open or runningNext primary completion: Nov 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly21 open or runningphase 1since Aug 5, 2022Aug 5, 2022Nov 2027phase 1 · NCT07883590

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 5, 2022First study: phase 1 study in HealthyFirst studyNCT05492201 · 84 enrolled · United Kingdom
  2. Oct 14, 2026Phase 1 study in Amyotrophic Lateral SclerosisNCT07883590 · 32 planned · United States, Canada

Ahead

  1. Nov 2027Primary completion: phase 1 study in Amyotrophic Lateral SclerosisNCT07883590

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07883590Amyotrophic Lateral Sclerosis · United States, Canada1Not yet recruitingNov 202732
NCT05492201Healthy · United Kingdom1CompletedApr 29, 202584

How it is read

Names in the registry

  • “LY3873862”, 2 entries

Codes read as this program: LY3873862.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.